

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE AND NOMINATION COMMITTEE

Ms. Chow Ching Man ("**Ms. Chow**") has been appointed as an independent non-executive director of the Company ("**INED**") and a member of each of the audit committee and nomination committee of the Company with effect from 2 August 2023.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND POSITIONS OF THE AUDIT COMMITTEE AND NOMINATION COMMITTEE

The board (the "**Board**") of directors (the "**Directors**") of Huakang Biomedical Holdings Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that Ms. Chow has been appointed as an INED and as a member of each of the audit committee and nomination committee of the Company with effect from 2 August 2023.

Ms. Chow, aged 38, has approximately 6 years of experiences working in various banks in Hong Kong and Singapore. Ms. Chow handled the day-to-day banking services and investment needs of banks' clients in the role of relationship manager or executive. Ms. Chow also worked for KPMG Taiwan for approximately a year where she coordinated and explored new business opportunities with bankers located in Asia.

Ms. Chow graduated from the National University of Singapore in 2006 with a degree in Bachelor of Social Science in Psychology.

Ms. Chow has entered into an appointment letter with the Company for an initial term of three years commencing from 2 August 2023 and will continue thereafter until terminated by either party serving not less than one month's written notice to the other party. Pursuant to the appointment letter, Ms. Chow is entitled to a director's emolument of HK\$100,000 per annum. Such fee is determined by reference to the Company's remuneration policy and will be subject to review by the remuneration committee of the Company from time to time. Save as disclosed above, Ms. Chow is not expected to receive any other remuneration for holding her office as an INED.

In accordance with the articles of association of the Company, Ms. Chow will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election. Ms. Chow will be subject to rotation requirements as contained in the articles of association of the Company and shall retire from office by rotation at least once every three years.

Save as disclosed above, as at the date of this announcement, Ms. Chow (i) does not hold any other position in the Company and other members of the Group; (ii) did not hold any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not possess any other major appointments or professional qualifications; (iv) does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company or any of its associated corporations which is required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Ms. Chow has confirmed that she has met the independence criteria set out in Rule 5.09 of the Rules Governing the Listing of Securities on GEM (“**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Save as disclosed above, the Board is not aware of any information which is discloseable nor is/was Ms. Chow involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters concerning Ms. Chow that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Ms. Chow for joining the Board.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 2 August 2023

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary, Mr. Chan Kin Sang and Chow Ching Man.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.